5-112815595-T-C
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_000038.6(APC):c.933+2T>C variant causes a splice donor change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000687 in 1,455,924 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000038.6 splice_donor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
APC | NM_000038.6 | c.933+2T>C | splice_donor_variant | ENST00000257430.9 | NP_000029.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
APC | ENST00000257430.9 | c.933+2T>C | splice_donor_variant | 5 | NM_000038.6 | ENSP00000257430 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.87e-7 AC: 1AN: 1455924Hom.: 0 Cov.: 29 AF XY: 0.00 AC XY: 0AN XY: 724510
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Familial adenomatous polyposis 1 Pathogenic:3
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Mar 18, 2016 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Feb 14, 2023 | This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 24, 2023 | This sequence change affects a donor splice site in intron 9 of the APC gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in APC are known to be pathogenic (PMID: 17963004, 20685668). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with familial adenomatous polyposis (PMID: 15459959, 20685668; Invitae). ClinVar contains an entry for this variant (Variation ID: 371831). Studies have shown that disruption of this splice site is associated with altered splicing resulting in unknown protein product impact (PMID: 15459959; Invitae). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
Classic or attenuated familial adenomatous polyposis Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Jul 10, 2024 | This variant causes a T to C nucleotide substitution at the +2 position of intron 9 of the APC gene. Splice site prediction tools predict that this variant may have a significant impact on RNA splicing. An RNA study demonstrated that the variant did not cause aberrant fragment formation as measured by RT-PCR (PMID: 15459959). However, abnormal RNA splicing has been observed in a set of samples tested (Ambry Genetics; ClinVar SCV000579785.6). This variant has been reported in multiple individuals affected with or suspected of familial adenomatous polyposis (PMID: 15459959, 20223039, 20685668). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). This variant creates an alternative donor site beginning with a GC dinucleotide. Some GC variant donor sites have been shown to generate variable levels of wild-type transcript (PMID: 31131953). Hence, this variant could be less penetrant than a conventional splice donor site loss variant. Different variants affecting the same splice donor site, c.933+1G>A, c.933+2T>A, and c.933+2T>G, are described as disease-causing (ClinVar variation ID: 233970, 1482958, 823172). Loss of APC function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Likely Pathogenic. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | May 18, 2023 | The c.933+2T>C intronic variant results from a T to C substitution two nucleotides after coding exon 8 in the APC gene. This alteration has been reported in many families with classic familial adenomatous polyposis (FAP) and segregates with disease in multiple families (Ambry internal data; Aretz et al. Human Mutat. 2004 Nov;24(5):370-80; Lagarde A et al. J. Med. Genet. 2010 Oct;47:721-2; Kerr SE et al. J. Mol. Diagn. 2013 Jan;15(1):31-43). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. No aberrant splicing was observed by one reported mRNA transcript analysis (Aretz et al. Human Mutat. 2004 Nov;24(5):370-80). However, internal RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at